Literature DB >> 3155643

Prognosis of surgically determined complete responders in advanced ovarian cancer.

D M Gershenson, L J Copeland, J T Wharton, E N Atkinson, N Sneige, C L Edwards, F N Rutledge.   

Abstract

From January 1971 through December 1981, 246 patients with advanced (Stages III and IV) epithelial ovarian cancer underwent second-look laparotomy at The University of Texas M. D. Anderson Hospital and Tumor Institute at Houston. Eighty-five of these patients had a complete response (negative second-look laparotomy) following treatment with a variety of chemotherapeutic regimens. Three patients had also received irradiation. Patients were analyzed according to pretreatment characteristics (age, FIGO stage, ascites, pleural effusion, histologic grade, tumor type, type of surgery, residual tumor diameter, initial clinical status) and by the number of biopsy specimens taken at second-look laparotomy. The probability of recurrence and the length of survival following a negative second-look laparotomy are statistically related to these characteristics. Twenty of the 85 patients (24%) developed recurrent disease 5 to 32 months after laparotomy. The estimated 2- and 5-year survival rates are 99% and 85%, respectively. Patients who achieve a surgically determined complete response have an excellent chance for long-term survival.

Entities:  

Mesh:

Year:  1985        PMID: 3155643     DOI: 10.1002/1097-0142(19850301)55:5<1129::aid-cncr2820550531>3.0.co;2-o

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

Review 1.  Second-look laparotomy for epithelial ovarian cancer: a reappraisal.

Authors:  C S Chu; S C Rubin
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

2.  Preclinical evaluation of Mab CC188 for ovarian cancer imaging.

Authors:  M Xu; M P Rettig; G Sudlow; B Wang; W J Akers; D Cao; D G Mutch; J F DiPersio; S Achilefu
Journal:  Int J Cancer       Date:  2012-01-11       Impact factor: 7.396

3.  Surgical second-look in epithelial ovarian cancer: high recurrence rate after negative results and lack of survival benefit limits its role in standard management.

Authors:  Salih Taşkın; Mete Güngör; Elif Aylin Taşkın; Fırat Ortaç
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-03-01

4.  The prognostic impact of duration of anemia during chemotherapy in advanced epithelial ovarian cancer.

Authors:  Jin Hwi Kim; Joon Mo Lee; Ki Sung Ryu; Yong Seok Lee; Yong Gyu Park; Soo Young Hur; Keun Ho Lee; Sung Ha Lee
Journal:  Oncologist       Date:  2011-06-24

5.  Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma.

Authors:  R C Leonard; G E Smart; J R Livingstone; M A Cornbleet; G R Kerr; S Fletcher; J N Webb; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma.

Authors:  Sungeun Kim; June-Key Chung; Soon-Beom Kang; Moon-Hong Kim; Jae Min Jeong; Dong Soo Lee; Myung Chul Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

7.  Sequential cisplatin/cyclophosphamide chemotherapy and abdominopelvic radiotherapy in the management of advanced ovarian cancer.

Authors:  J A Green; H M Warenius; R D Errington; S Myint; G Spearing; A J Slater
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

8.  Diagnosis of persistent ovarian carcinoma with three-step immunoscintigraphy.

Authors:  P Magnani; F Fazio; C Grana; C Songini; L Frigerio; S Pecorelli; G Mangili; N Colombo; C D Mariani; G Paganelli
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

9.  Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial.

Authors:  T Dell' Anna; M Signorelli; P Benedetti-Panici; A Maggioni; R Fossati; R Fruscio; R Milani; L Bocciolone; A Buda; C Mangioni; G Scambia; R Angioli; E Campagnutta; R Grassi; F Landoni
Journal:  Br J Cancer       Date:  2012-08-02       Impact factor: 7.640

10.  The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma.

Authors:  J Fisken; R C Leonard; M Stewart; G J Beattie; C Sturgeon; L Aspinall; J E Roulston
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.